Hormone Replacement Therapy Market, by Therapy Type (Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, and Testosterone Replacement Therapy), by Route of Administration (Oral, Parenteral, and Others

Hormone Replacement Therapy Market, by Therapy Type (Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, and Testosterone Replacement Therapy), by Route of Administration (Oral, Parenteral, and Others), by Application (Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Hormone replacement therapy (HRT) can help balance estrogen and progesterone levels during or near menopause. Hormone replacement therapy (HRT) is a treatment to relieve symptoms of menopause. It replaces hormones that are at a lower level as approach the menopause. During menopause, estrogen levels fall. Some women get uncomfortable symptoms such as hot flashes and vaginal dryness. HRT (also known as hormone therapy, menopausal hormone therapy, and estrogen replacement therapy) is the most effective treatment for menopause symptoms. The benefits of hormone replacement therapy are that it relieves hot flashes and night sweats, helps sleep better, eases vaginal dryness and itching, makes sexual intercourse less painful, helps prevent fractures caused by osteoporosis (thinning bones), make some women less likely to have heart disease, and lowers chances of dementia.

Market Dynamics

Rising number of generic versions of hormone replacement therapies by various manufacturers would drive growth of market in terms of volume and value. For instance, Teva Pharmaceutical Industries Ltd. launched the generic Axiron1 (testosterone) topical solution CIII, 30 mg/1.5 mL, in the U.S. on August 18, 2017 to treat adult males who have low or no testosterone due to certain medical conditions. This solution was supplied in a metered dose pump with an underarm applicator. Moreover, in April 2022, Lupin Limited, a pharmaceutical company, launched Merzee capsules, a medication used to prevent pregnancy, in the U.S. market. Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Allergan Pharmaceuticals' Taytulla capsules. The Lupin Limited, India-based drug maker had launched the product in the U.S. market under exclusive license, marketing and distribution agreement with Slayback Pharma LLC, a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products from Lupin Ltd.

Key features of the study:

• This report provides an in-depth analysis of the global hormone replacement therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hormone replacement therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Abbott Laboratories, Mylan NV, Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global hormone replacement therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hormone replacement therapy market

Detailed Segmentation:

• Global Hormone Replacement Therapy Market, By Therapy Type:
• Estrogen Replacement Therapy
• Human Growth Hormone (HGH) Replacement Therapy
• Thyroid Replacement Therapy
• Testosterone Replacement Therapy
• Global Hormone Replacement Therapy Market, By Route Of Administration:
• Oral
• Parenteral
• Others
• Global Hormone Replacement Therapy Market, By Application:
• Hypothyroidism
• Male Hypogonadism
• Growth Hormone Deficiency
• Menopause
• Others
• Global Hormone Replacement Therapy Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Hormone Replacement Therapy Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Novartis AG*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Abbott Laboratories
• Mylan NV
• Merck KgaA
• Bayer AG
• Pfizer Inc.
• Novo Nordisk A/S
• QuatRx Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Amgen, Inc.
• Eli Lilly and Company

“*” marked represents similar segmentation in other categories in the respective section.